Abstract
Pancreatic cancer remains a worldwide issue and burden that is hard to resolve given its low resection rate and chemo-resistance. Early diagnosis and early treatment are critical for conquering pancreatic cancer. Therefore, new biomarkers for diagnosis and prognosis are urgently needed. Previously, researchers mainly focused on protein-coding genetic and epigenetic changes in many types of cancers, and regarded the noncoding part as waste. Recently, however, long non-coding RNA (lncRNA) has emerged as a major participant in carcinogenesis, as it regulates cell proliferation, migration, invasion, metastasis, chemo-resistance, etc. The underlying mechanisms are summarized as signaling, decoy, guide and scaffold, yet the specific regulation networks remain to be uncovered. Several studies have revealed that some lncRNAs are dysregulated in pancreatic cancer, participating in biological functions. In this review, we will briefly outline the functional lncRNAs in pancreatic cancer, decipher possible mechanisms of lncRNAs, and further explore their significance in pancreatic cancer.
Keywords: Long non-coding RNA, pancreatic cancer, biomarkers, carcinogenesis, treatment, targets.
Current Molecular Medicine
Title:Long Non-Coding RNA: An Emerging Paradigm of Pancreatic Cancer
Volume: 16 Issue: 8
Author(s): T. Han, H. Hu, M. Zhuo, L. Wang, J.-J. Cui, F. Jiao and L.-W. Wang
Affiliation:
Keywords: Long non-coding RNA, pancreatic cancer, biomarkers, carcinogenesis, treatment, targets.
Abstract: Pancreatic cancer remains a worldwide issue and burden that is hard to resolve given its low resection rate and chemo-resistance. Early diagnosis and early treatment are critical for conquering pancreatic cancer. Therefore, new biomarkers for diagnosis and prognosis are urgently needed. Previously, researchers mainly focused on protein-coding genetic and epigenetic changes in many types of cancers, and regarded the noncoding part as waste. Recently, however, long non-coding RNA (lncRNA) has emerged as a major participant in carcinogenesis, as it regulates cell proliferation, migration, invasion, metastasis, chemo-resistance, etc. The underlying mechanisms are summarized as signaling, decoy, guide and scaffold, yet the specific regulation networks remain to be uncovered. Several studies have revealed that some lncRNAs are dysregulated in pancreatic cancer, participating in biological functions. In this review, we will briefly outline the functional lncRNAs in pancreatic cancer, decipher possible mechanisms of lncRNAs, and further explore their significance in pancreatic cancer.
Export Options
About this article
Cite this article as:
Han T., Hu H., Zhuo M., Wang L., Cui J.-J., Jiao F. and Wang L.-W., Long Non-Coding RNA: An Emerging Paradigm of Pancreatic Cancer, Current Molecular Medicine 2016; 16 (8) . https://dx.doi.org/10.2174/1566524016666160927095812
DOI https://dx.doi.org/10.2174/1566524016666160927095812 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cancer-Specific Ligands Identified from Screening of Peptide-Display Libraries
Current Pharmaceutical Design HSP27: Mechanisms of Cellular Protection Against Neuronal Injury
Current Molecular Medicine Prospectives of Antihypertensive Nano-ceuticals as Alternative Therapeutics
Current Drug Targets An Insight into the Therapeutic Potential of Major Coffee Components
Current Drug Metabolism Determination of Human Serum α1-Acid Glycoprotein and Albumin Binding of Various Marketed and Preclinical Kinase Inhibitors
Current Medicinal Chemistry Pharmacological Modulation of Reactive Oxygen Species in Cancer Treatment
Current Drug Targets Antigen-specific Immunotherapy in Ovarian Cancer and p53 as Tumor Antigen
Current Pharmaceutical Design Carotenoids as Modulators of Intracellular Signaling Pathways
Current Signal Transduction Therapy Classes of Sigma2 (σ2) Receptor Ligands: Structure Affinity Relationship (SAfiR) Studies and Antiproliferative Activity
Current Pharmaceutical Design Targeting Cell Death and Survival Receptors in Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Potential Usage of ING Family Members in Cancer Diagnostics and Molecular Therapy
Current Drug Targets Prospective Teratology of Retinoic Acid Metabolic Blocking Agents (RAMBAs) and Loss of CYP26 Activity
Current Pharmaceutical Design A New Target for Diagnosis and Treatment of CNS Disorders: Agmatinergic System
Current Medicinal Chemistry MicroRNAs and the Response of Prostate Cancer to Anti-Cancer Drugs
Current Drug Targets Sphingosine Kinases Signalling in Carcinogenesis
Mini-Reviews in Medicinal Chemistry Counteracting PINK/Parkin Deficiency in the Activation of Mitophagy: A Potential Therapeutic Intervention for Parkinson’s Disease
Current Neuropharmacology Recent Advances of Metallocenes for Medicinal Chemistry
Mini-Reviews in Medicinal Chemistry p73 as a Pharmaceutical Target for Cancer Therapy
Current Pharmaceutical Design Presynaptic Cell Dependent Modulation of Inhibition in Cortical Regions
Current Neuropharmacology Antidepressants, β-Arrestins and GRKs: From Regulation of Signal Desensitization to Intracellular Multifunctional Adaptor Functions
Current Pharmaceutical Design